SEC Form 4 · accession 0001628280-26-058417
REPLIGEN CORP · RGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Olivier Loeillot
Officer — Chief Executive Officer · Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 21, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000730272
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2026 | M | 5,426 | $141.79 | A | 59,672 | D | |
| Common Stock | Aug 20, 2026 | S | 5,426 | $180.00 | D | 54,246 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $141.79 | Aug 20, 2026 | M | 5,426 | D | — | Sep 3, 2034 | Common Stock | 5,426 | 10,852 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
- F25,426 shares will vest on each of September 3, 2026, and September 3, 2027.